DAX19.105 +0,5%ESt504.740 +0,2%MSCIW3.725 -0,2%Dow43.439 +0,1%Nas18.721 -1,3%Bitcoin91.773 +2,7%Euro1,0536 -0,1%Öl73,92 +1,1%Gold2.668 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Bayer BAY001 Tesla A1CX3T Rheinmetall 703000 Porsche PAG911 Volkswagen (VW) vz. 766403 Coinbase A2QP7J Mercedes-Benz Group (ex Daimler) 710000 Palantir A2QA4J Amazon 906866 Siemens Energy ENER6Y Deutsche Telekom 555750 NEL ASA A0B733 EVOTEC 566480
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Anleger unentschlossen: DAX stabil -- Wall Street fällt ins Minus-- NVIDIA übertrifft Erwartungen -- Bitcoin: Neuer Rekord -- Mercedes: Sparkurs -- MicroStrategy, Medios, Rheinmetall im Fokus
Top News
Unilever-Aktie mit Verlusten: Unilever plant nun Börsengang statt Verkauf für Eiscreme-Geschäft Unilever-Aktie mit Verlusten: Unilever plant nun Börsengang statt Verkauf für Eiscreme-Geschäft
Mercedes-Benz-Aktie verliert: Mercedes-Benz will Milliarden einsparen Mercedes-Benz-Aktie verliert: Mercedes-Benz will Milliarden einsparen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Marketing-Anzeige: Mit Solidvest investieren und 1% Bonus on top sichern +++ die Online-Vermögensverwaltung mit Aktien und Anleihen von DJE.

Lannett Aktie

NeuKaufenVerkaufen
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

WKN882871

ISINUS5160121019

SymbolLCI

Lannett Aktien News

DatumMeistgelesen
PR NewswireLannett Company, Inc. Enters Into Restructuring Support Agreement
PR NewswireNYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
PR NewswireLANNETT SHARES UPDATE
PR NewswireLANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT
PR NewswireLANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
PR NewswireLANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
PR NewswireLANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
PR NewswireLANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE
PR NewswireLANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2
PR NewswireLANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT
PR NewswireLANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS
PR NewswireLANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
PR NewswireLANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24
PR NewswireLANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
PR NewswireLANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP
PR NewswireLANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS
PR NewswireLANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4
PR NewswireLANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
PR NewswireLANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE
PR NewswireLANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14
PR NewswireLANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE
PR NewswireLANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million
PR NewswireLANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE
PR NewswireLANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3
PR NewswireLANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
PR NewswireLANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

Lannett News

Lannett News: auf dieser Seite finden Sie alle Lannett News und Nachrichten zur Lannett Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Lannett News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Lannett News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.